Longer T2D survival with Metformin

New research has found that treatment with metformin is significantly linked with reduced mortality in people with Type 2 diabetes, compared with treatment with other anti-diabetes drug classes. Treatment with a sodium-glucose cotransporter 2 inhibitor (SGLT2i) was also found to be significantly associated with increased longevity, compared with treatment with other glucose-lowering medications. The survival of people with Type 2 diabetes on SGLT2i treatment approximated that of people without diabetes, and SGLT2i treatment was also linked with significantly lower cancer-related mortality. These results should encourage clinicians to consider metformin and an SGLT2i agent for either single- or dual-drug first-line treatment of people with Type 2 diabetes.

To read more, CLICK HERE.

Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).

Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags